Blueprint Medicines — Technical Presentation (April 2018)
25 slides from Blueprint Medicines's technical presentation, Apr 16, 2018
Slide 1: BLU-667 achieves proof of concept in ARROW, a phase 1 study of RET-altered solid tumors
1 Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors Vivek Subbiah1, Matthew Taylor2, Jessica Lin3, Mimi Hu1, Sai-Hong Ignatius Ou4, Marcia S. Brose5, Elena Garralda6, Corinne Clifford7, Michael Palmer7, Meera
Slide 2: Disclosures
2 Disclosures BLU-667 is an investigational agent discovered and currently in development by Blueprint Medicines Corporation (Blueprint Medicines) I have the following financial relationships to disclose: Grant/Research support from: Blueprint Medicines Corporation Novartis International AG Bayer AG
Slide 3: Receptor tyrosine kinase RET: normal signaling
Receptor tyrosine kinase, REarranged during Transfection (RET) Organ development and tissue homeostasis RET Receptor Tyrosine Kinase GDNF ligand GFRα1 TK1 TK2 RAS/RAF/MEK/ERK Normal RET signaling 3
Slide 4: Oncogenic RET signaling: activating mutations and fusions
Receptor tyrosine kinase, REarranged during Transfection (RET) Activating RET mutations* C620/C634 Dimeric RET fusions KIF5B-, CCDC6-,NCOA4, TRIM-33- and more partners V804L/M M918T Organ development and tissue homeostasis RET Proto-oncogene GDNF ligand GFRα1 TK1 TK2 Oncogenic RET signaling Normal R
Slide 5: RET is a rare driver of multiple, diverse tumor types
5 RET is a rare driver of multiple, diverse tumor types 1. Drilon A et al. Nat Rev Clin Oncol. 2018;15:151-67 2.Kato S, et al. Clin Cancer Res 2017;23:1988-1997. Colorectal cancer Non-small cell lung cancer ~1-2% RET-fusions Medullary thyroid cancer >60% RET-mutations Papillary thyroid cancer ~10% R
Slide 6: Patients with RET-alterations have not benefited from precision oncology
6 Patients with RET-alterations have not benefited from precision oncology MKI, multikinase inhibitors; MTC, medullary thyroid cancer; NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival; RTK, receptor tyrosine kinase Precision oncology Non-small cell lung c
Slide 7: Patients with RET-alterations have not benefited from precision oncology
7 Patients with RET-alterations have not benefited from precision oncology MKI, multikinase inhibitors; MTC, medullary thyroid cancer; NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival; RTK, receptor tyrosine kinase Precision oncology Non-small cell lung c
Slide 8: BLU-667 was designed to treat RET-altered cancers
8 BLU-667 was designed to treat RET-altered cancers Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI) (www.cellsignal.com). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content Kinome selectivity for RET Variant Bioch
Slide 9: BLU-667 potently inhibits RET-driven tumor growth
9 BLU-667 potently inhibits RET-driven tumor growth Potent Pathway inhibition KIF5B-RET NSCLC patient-derived xenograft1 Vehicle 3 mg/kg BID 10 mg/kg BID 30 mg/kg BID 60 mg/kg QD RET ERK DUSP6 / SPRY4 MEK BID, two times per day; QD, once daily 1. Subbiah V et al. Cancer Discovery April 15 2018 0 250
Slide 10: ARROW first-in-human study design
MTD Tablets will go to US first 10 BLU-667 ARROW first-in-human study BOIN, Bayesian optimal interval; MTD, maximum tolerated dose Part 1: Dose escalation – completed Part 2: Dose expansion – enrolling NSCLC No prior kinase inhibitor NSCLC Failed prior kinase inhibitor Medullary Thyroid Cancer Key o
Slide 11: Demography and baseline characteristics
11 Demography and baseline characteristics ECOG PS, Eastern Cooperative Oncology Group performance score Data cut-off: April 6, 2018 Parameter (N=53) Age, years; median (range) 56 (19-83) Sex, male; n (%) 30 (57) ECOG PS; n (%) 0 1 21 (40) 32 (60) Metastatic disease; n (%) 50 (94) Tumor type; n (%)
Slide 12: Diverse RET genotypes enrolled
Diverse RET genotypes enrolled Medullar thyroid cancer N=29 Other RET 10% Multiple 7% V804M 4% C634R 7% M918T72% RET Mutations KIAA 1468-5% RET FISH+ 11% Non-small cell lung cancer N=19 RET Fusions CCDC6 21% KIF5B 63% Paraganglioma N=1 RET R77H Papillary thyroid cancer N=2 CCDC6-RET 100% Data cut-of
Slide 13: Dose escalation results
13 Dose escalation results ALT, alanine aminotransferase Data cut-off: April 6, 2018 Dose (mg QD) # Evaluable (N=49) Dose limiting toxicity 30 1 None 60 6 None 100 5 Alanine transaminase increased (1) 200 12 None 300 11 Tumor lysis syndrome (1) Hypertension (1) 400 10 Asthenia (1) Hypertension (1) 6
Slide 14: Dose-dependent exposure and RET pathway inhibition
14 Dose-dependent exposure and RET pathway inhibition Tumor Pharmacodynamics Steady-state Pharmacokinetics Plasma IC90 Brain IC90 30 mg QD 60 mg QD 100 mg QD 200 mg QD 300 mg QD 400 mg QD 600 mg QD RET ERK DUSP6 / SPRY4 MEK 1 10 100 1000 10000 0 5 10 15 20 25 BLU - 667 mean plasma concentration (ng/
Slide 15: Dose-dependent decline in MTC tumor markers
15 Dose-dependent decline in MTC tumor markers 60 mg QD 100 mg QD 200 mg QD 300 mg QD Data cut-off: April 6, 2018 -100 -75 -50 -25 0 25 200 300 200 60 60 200 300 100 100 200 200 60 300 200 200 60 300 300 300 300 % reduction in CD21 Carcinoembryonic antigen (CEA) -100 -75 -50 -25 0 25 60 200 300 60 2
Slide 16: Potent activity against highly invasive RET-mutant MTC
16 Potent activity against highly invasive RET-mutant MTC 27-year-old male; RET L629-D361 Del; initiated at 60 mg; ongoing at 400 mg with confirmed PR Baseline Month 4 60 mg 100 mg 190 mg 200 mg 300 mg BLU-667 dose 0 1 2 3 4 5 6 7 8 9 10 Month -50% -40% -30% -20% -10% 0% 10% 0% 20% 40% 60% 80% 100%
Slide 17: Potent activity against KIF5B-RET NSCLC – post chemotherapy
Potent activity against KIF5B-RET NSCLC – post chemotherapy 17 FISH Breakpoint FUSION KIF5B 10p11.22 RET 10q11.21 KIF5B Exons 1-15 Chr10:32315000 RET Exons 12-20 Chr10:43610000 Baseline Month 4 37-year-old female; ongoing at 400 mg with confirmed PR 300 mg BLU-667 Dose 200 mg 0 1 2 3 4 5 6 7 8 9 Mon
Slide 18: Potent activity against KIF5B-RET NSCLC – post-vandetinib+everolimus
18 Potent activity against KIF5B-RET NSCLC – post-vandetinib+everolimus 74-year-old male; initiated at 300 mg; ongoing at 400 mg; PR at month 5 pending confirmation Baseline First Assessment (Month 2) Subbiah V et al. Cancer Discovery April 15 2018
Slide 19: Activity against KIF5B-RET NSCLC brain metastases
19 Activity against KIF5B-RET NSCLC brain metastases 69-year-old male; initiated at 400 mg; ongoing at month 4 Baseline First assessment (Month 2) Images courtesy of Drs. Gainor, J and Lin, J of MGH
Slide 20: BLU-667 has broad anti-tumor activity against RET-altered cancers
20 BLU-667 has broad anti-tumor activity against RET-altered cancers Data cut-off: April 6, 2018 C, prior chemotherapy; CR, complete response; I, prior immunotherapy; M, prior MKI therapy; MKI, multikinase inhibitor; PD, progressive disease; PR, partial response; SD, stable disease PD SD PR Best Res
Slide 21: Durable activity and high response rate in RET-altered NSCLC
21 BLU-667 has durable activity and high response rate in RET-altered NSCLC Treatment Duration (days) KIF5B KIAA1468 CCDC6 RET FISH+ Prior Therapy 1 29 57 85 113 141 169 197 225 253 281 309 337 365 Treatment duration: Median 3.9 months Range 0.4–11.4 months 13/19 (68%) on treatment Best Response Eva
Slide 22: Durable activity and high response rate in RET-altered MTC
22 BLU-667 has durable activity and high response rate in RET-altered MTC L629-D361 Del V388A/C634R C634R RET In/Del M918T E632_1638 Del Other RET V804M Prior Therapy Treatment duration: Median 4.7 months Range 0.5–11.5 months 25/29 (86%) on treatment Treatment Duration (days) 1 29 57 85 113 141 169
Slide 23: BLU-667 is well tolerated
23 BLU-667 is well tolerated AE, adverse event; ALP, alkaline phosphatase; ALT, analine aminotransferase; AST, aspartate aminotransferase; CTCAE, common terminology criteria for adverse events Data cut-off: April 6, 2018 Treatment-emergent Adverse Events ≥10% per CTCAE (30-400 mg Safety Population,
Slide 24: Conclusions
BLU-667 delivers: Potent RET pathway inhibition with favorable tolerability Broad anti-tumor activity regardless of RET genotype, indication and prior therapy High preliminary response rates and durable activity ORR: RET-fusion NSCLC 50% ORR: RET-mutant MTC 40% ORR: RET-fusions and mutations (NSCLC,
Slide 25: Acknowledgements
We thank the participating patients, their families, all study co-investigators, and research co-ordinators at the following institutions: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, United States The Knight Cancer Institute Oregon H
Blueprint Medicines — Technical Presentation (April 2018) on 6ix